Szekanecz Z - Search Results

1

Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.

Taylor PC, Choy E, Baraliakos X, Szekanecz Z, Xavier RM, Isaacs JD, Strengholt S, Parmentier JM, Lippe R, Tanaka Y. Taylor PC, et al. Among authors: szekanecz z. Rheumatology (Oxford). 2024 Feb 1;63(2):298-308. doi: 10.1093/rheumatology/kead448. Rheumatology (Oxford). 2024. PMID: 37624925 Free PMC article. Review.

2

2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis.

Grayson PC, Ponte C, Suppiah R, Robson JC, Gribbons KB, Judge A, Craven A, Khalid S, Hutchings A, Danda D, Luqmani RA, Watts RA, Merkel PA; DCVAS Study Group. Grayson PC, et al. Arthritis Rheumatol. 2022 Dec;74(12):1872-1880. doi: 10.1002/art.42324. Epub 2022 Nov 8. Arthritis Rheumatol. 2022. PMID: 36349501

3

2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis.

Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, Craven A, Khalid S, Hutchings A, Watts RA, Merkel PA, Luqmani RA; DCVAS Study Group. Ponte C, et al. Arthritis Rheumatol. 2022 Dec;74(12):1881-1889. doi: 10.1002/art.42325. Epub 2022 Nov 8. Arthritis Rheumatol. 2022. PMID: 36350123

4

2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis.

Grayson PC, Ponte C, Suppiah R, Robson JC, Gribbons KB, Judge A, Craven A, Khalid S, Hutchings A, Danda D, Luqmani RA, Watts RA, Merkel PA; DCVAS Study Group. Grayson PC, et al. Ann Rheum Dis. 2022 Dec;81(12):1654-1660. doi: 10.1136/ard-2022-223482. Epub 2022 Nov 9. Ann Rheum Dis. 2022. PMID: 36351705

5

2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis.

Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, Craven A, Khalid S, Hutchings A, Watts RA, Merkel PA, Luqmani RA; DCVAS Study Group. Ponte C, et al. Ann Rheum Dis. 2022 Dec;81(12):1647-1653. doi: 10.1136/ard-2022-223480. Epub 2022 Nov 9. Ann Rheum Dis. 2022. PMID: 36351706

6

Can we define difficult-to-treat systemic sclerosis?

Szűcs G, Szamosi S, Szekanecz Z. Szűcs G, et al. Among authors: szekanecz z. Expert Rev Clin Immunol. 2024 May 7. doi: 10.1080/1744666X.2024.2352450. Online ahead of print. Expert Rev Clin Immunol. 2024. PMID: 38711393 Review.

7

[Monogenic and acquired autoinflammatory diseases].

Szekanecz Z, Szamosi S, Benkő S, Szűcs G. Szekanecz Z, et al. Orv Hetil. 2024 May 5;165(18):683-697. doi: 10.1556/650.2024.33038. Print 2024 May 5. Orv Hetil. 2024. PMID: 38709575 Review. Hungarian.

8

Granulomatosis with polyangiitis or its mimic? A case report.

Major T, Nagy G, Szabó J, Mózes H, Szűcs G, Szekanecz Z, Szamosi S. Major T, et al. Among authors: szekanecz z. J Int Med Res. 2024 Apr;52(4):3000605241237876. doi: 10.1177/03000605241237876. J Int Med Res. 2024. PMID: 38606757 Free PMC article.

9

Natural Autoantibodies in Biologic-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients: Associations with Vascular Pathophysiology.

Simon D, Kacsándi D, Pusztai A, Soós B, Végh E, Kerekes G, Bodoki M, Szamosi S, Szűcs G, Prohászka Z, Németh P, Berki T, Szekanecz Z. Simon D, et al. Among authors: szekanecz z. Int J Mol Sci. 2024 Mar 18;25(6):3429. doi: 10.3390/ijms25063429. Int J Mol Sci. 2024. PMID: 38542402 Free PMC article.

10

Current status of immunological therapies for rheumatoid arthritis with a focus on antigen-specific therapeutic vaccines.

Zimmerman DH, Szekanecz Z, Markovics A, Rosenthal KS, Carambula RE, Mikecz K. Zimmerman DH, et al. Among authors: szekanecz z. Front Immunol. 2024 Mar 6;15:1334281. doi: 10.3389/fimmu.2024.1334281. eCollection 2024. Front Immunol. 2024. PMID: 38510240 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

371 results

Search Page